Aspire Biopharma (ASBP) Competitors

Aspire Biopharma logo
$7.65 -0.24 (-3.04%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$8.00 +0.35 (+4.58%)
As of 11/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ASBP vs. INVZ, WKSP, MKDW, UCAR, and REE

Should you buy Aspire Biopharma stock or one of its competitors? Aspire Biopharma's main competitors and comparable companies include Innoviz Technologies (INVZ), Worksport (WKSP), MKDWELL Tech (MKDW), U Power (UCAR), and REE Automotive (REE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "automotive parts & equipment" industry.

How does Aspire Biopharma compare to Innoviz Technologies?

Aspire Biopharma (NASDAQ:ASBP) and Innoviz Technologies (NASDAQ:INVZ) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Innoviz Technologies has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Aspire Biopharma has higher earnings, but lower revenue than Innoviz Technologies. Innoviz Technologies is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aspire Biopharma$10K1,071.00-$24.48M-$69.62N/A
Innoviz Technologies$55.09M0.44-$67.79M-$0.37N/A

Innoviz Technologies has a net margin of -171.19% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Innoviz Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Aspire Biopharma-11,362.21% N/A -177.59%
Innoviz Technologies -171.19%-138.98%-67.99%

In the previous week, Innoviz Technologies had 5 more articles in the media than Aspire Biopharma. MarketBeat recorded 6 mentions for Innoviz Technologies and 1 mentions for Aspire Biopharma. Innoviz Technologies' average media sentiment score of -0.35 beat Aspire Biopharma's score of -0.71 indicating that Innoviz Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aspire Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
Innoviz Technologies
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 63.3% of Innoviz Technologies shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by insiders. Comparatively, 11.2% of Innoviz Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Innoviz Technologies has a consensus target price of $0.20, suggesting a potential upside of 78.25%. Given Innoviz Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Innoviz Technologies is more favorable than Aspire Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aspire Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Innoviz Technologies
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Innoviz Technologies beats Aspire Biopharma on 11 of the 14 factors compared between the two stocks.

How does Aspire Biopharma compare to Worksport?

Worksport (NASDAQ:WKSP) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap consumer discretionary companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Worksport had 11 more articles in the media than Aspire Biopharma. MarketBeat recorded 12 mentions for Worksport and 1 mentions for Aspire Biopharma. Worksport's average media sentiment score of 0.76 beat Aspire Biopharma's score of -0.71 indicating that Worksport is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Worksport
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aspire Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

Worksport has a net margin of -95.65% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Worksport's return on equity.

Company Net Margins Return on Equity Return on Assets
Worksport-95.65% -97.20% -69.14%
Aspire Biopharma -11,362.21%N/A -177.59%

Worksport has higher revenue and earnings than Aspire Biopharma. Worksport is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Worksport$16.10M0.35-$19.35M-$1.85N/A
Aspire Biopharma$10K1,071.00-$24.48M-$69.62N/A

Worksport presently has a consensus price target of $2.00, suggesting a potential upside of 611.24%. Given Worksport's stronger consensus rating and higher probable upside, analysts plainly believe Worksport is more favorable than Aspire Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Worksport
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aspire Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

16.1% of Worksport shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 5.8% of Worksport shares are held by insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Worksport has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Summary

Worksport beats Aspire Biopharma on 12 of the 15 factors compared between the two stocks.

How does Aspire Biopharma compare to MKDWELL Tech?

MKDWELL Tech (NASDAQ:MKDW) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap consumer discretionary companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

MKDWELL Tech has higher revenue and earnings than Aspire Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MKDWELL Tech$3.03M0.81-$2.57MN/AN/A
Aspire Biopharma$10K1,071.00-$24.48M-$69.62N/A

In the previous week, MKDWELL Tech had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for MKDWELL Tech and 1 mentions for Aspire Biopharma. MKDWELL Tech's average media sentiment score of -0.67 beat Aspire Biopharma's score of -0.71 indicating that MKDWELL Tech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MKDWELL Tech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Aspire Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

MKDWELL Tech has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%.

Company Net Margins Return on Equity Return on Assets
MKDWELL TechN/A N/A N/A
Aspire Biopharma -11,362.21%N/A -177.59%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MKDWELL Tech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aspire Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

70.0% of MKDWELL Tech shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 22.9% of MKDWELL Tech shares are owned by insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MKDWELL Tech has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Summary

MKDWELL Tech beats Aspire Biopharma on 8 of the 10 factors compared between the two stocks.

How does Aspire Biopharma compare to U Power?

U Power (NASDAQ:UCAR) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap consumer discretionary companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

U Power has a beta of 7.81, suggesting that its stock price is 681% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

In the previous week, Aspire Biopharma had 1 more articles in the media than U Power. MarketBeat recorded 1 mentions for Aspire Biopharma and 0 mentions for U Power. U Power's average media sentiment score of 0.00 beat Aspire Biopharma's score of -0.71 indicating that U Power is being referred to more favorably in the media.

Company Overall Sentiment
U Power Neutral
Aspire Biopharma Negative

13.2% of U Power shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

U Power has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%.

Company Net Margins Return on Equity Return on Assets
U PowerN/A N/A N/A
Aspire Biopharma -11,362.21%N/A -177.59%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
U Power
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Aspire Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

U Power has higher revenue and earnings than Aspire Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
U Power$5.85M0.64-$9.78MN/AN/A
Aspire Biopharma$10K1,071.00-$24.48M-$69.62N/A

Summary

U Power beats Aspire Biopharma on 7 of the 11 factors compared between the two stocks.

How does Aspire Biopharma compare to REE Automotive?

Aspire Biopharma (NASDAQ:ASBP) and REE Automotive (NASDAQ:REE) are both small-cap consumer discretionary companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Aspire Biopharma had 1 more articles in the media than REE Automotive. MarketBeat recorded 1 mentions for Aspire Biopharma and 0 mentions for REE Automotive. REE Automotive's average media sentiment score of 0.00 beat Aspire Biopharma's score of -0.71 indicating that REE Automotive is being referred to more favorably in the news media.

Company Overall Sentiment
Aspire Biopharma Negative
REE Automotive Neutral

REE Automotive has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%.

Company Net Margins Return on Equity Return on Assets
Aspire Biopharma-11,362.21% N/A -177.59%
REE Automotive N/A N/A N/A

Aspire Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, REE Automotive has a beta of 2.4, indicating that its share price is 140% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aspire Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
REE Automotive
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 12.7% of REE Automotive shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aspire Biopharma has higher earnings, but lower revenue than REE Automotive. Aspire Biopharma is trading at a lower price-to-earnings ratio than REE Automotive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aspire Biopharma$10K1,071.00-$24.48M-$69.62N/A
REE Automotive$1.30M1.87-$55.81M-$5.28N/A

Summary

REE Automotive beats Aspire Biopharma on 6 of the 11 factors compared between the two stocks.

Get Aspire Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASBP vs. The Competition

MetricAspire BiopharmaAutomobile Components IndustryConsumer Discretionary SectorNASDAQ Exchange
Market Cap$11.07M$4.22B$12.80B$11.70B
Dividend YieldN/A2.36%3.13%4.65%
P/E RatioN/A15.9324.2126.75
Price / Sales1,071.001.141.735.51
Price / CashN/A9.6315.2521.66
Price / Book-0.141.453.423.65
Net Income-$24.48M$74.66M$445.49M$394.00M
7 Day Performance-9.04%-3.84%-3.27%-5.74%
1 Month Performance-12.27%-7.28%-4.12%-9.54%
1 Year Performance-93.47%-5.48%-1.75%-6.71%

Aspire Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASBP
Aspire Biopharma
0.8297 of 5 stars
$7.65
-3.0%
N/A-93.6%$11.07M$10KN/A2
INVZ
Innoviz Technologies
2.4516 of 5 stars
$0.17
-6.7%
$2.00
+1,051.4%
-91.2%$39.92M$55.09MN/A372
WKSP
Worksport
3.6752 of 5 stars
$0.34
-2.9%
$2.00
+488.2%
-86.2%$7.09M$16.10MN/A122
MKDW
MKDWELL Tech
0.4745 of 5 stars
$0.12
-19.6%
N/A-98.7%$5.13M$3.03MN/A91
UCAR
U Power
0.5071 of 5 stars
$2.95
+0.7%
N/A-99.2%$3.77M$5.85MN/A86

Related Companies and Tools


This page (NASDAQ:ASBP) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners